VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the stock.

A number of other brokerages have also recently issued reports on VNRX. D. Boral Capital reiterated a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a report on Tuesday, December 10th. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.

VolitionRx Stock Down 7.4 %

Shares of VNRX opened at $0.57 on Friday. The stock has a market cap of $52.36 million, a P/E ratio of -1.57 and a beta of 1.17. The business’s fifty day moving average is $0.68 and its 200 day moving average is $0.66. VolitionRx has a 12-month low of $0.43 and a 12-month high of $1.23.

Insider Buying and Selling

In related news, CEO Cameron John Reynolds acquired 139,811 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were bought at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the purchase, the chief executive officer now owns 2,117,404 shares in the company, valued at $1,206,920.28. This trade represents a 7.07 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Guy Archibald Innes bought 174,764 shares of the business’s stock in a transaction on Monday, December 9th. The stock was bought at an average price of $0.57 per share, with a total value of $99,615.48. Following the purchase, the director now owns 617,085 shares in the company, valued at $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 358,266 shares of company stock worth $204,212. Insiders own 12.80% of the company’s stock.

Institutional Trading of VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC boosted its stake in VolitionRx Limited (NYSE:VNRX) by 78.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.